Pralatrexate – Uses, Dosage, Side Effects, Interaction Pralatrexate is a folate analog inhibitor of dihydrofolate reductase (DHFR) exhibiting a high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylation and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylation pralatrexate, which is more readily affixed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at the highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types. Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T-cell lymphomas. Pralatrexate has been associated with a modest rate of serum enzyme elevations during therapy but has not been convincingly linked to instances of acute, clinically apparent liver injury. Pralatrexate is a pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma. It has a role as an antineoplastic agent, an antimetabolite, and an EC 1.5.1.3 (dihydrofolate reductase) inhibitor. It is an N-acyl-L-glutamic acid, a member of pteridines, and a terminal acetylenic compound. Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma. Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cell counterparts Compared to methotrexate, pralatrexate has better accumulation in cancer cells Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC.[rx] Pralatrexate was approved by the FDA on September 24, 2009. It is also being studied for other types of lymphoma and solid malignancy such as non-small-cell lung cancer, breast cancer, and bladder cancer.[rx] Mechanism of Action The selectivity of pralatrexate for cancer cells is based upon the observation that cancer cells generally have overexpression of reduced folate carrier protein-1 (RTC-1) compared to normal somatic cells. This carrier protein allows the entrance of pralatrexate into the cell. Upon entering the cell, folypolyglutamate synthase FPGS catalyzes the polyglutamylation of pralatrexate so that it is retained inside the cell. Once inside, pralatrexate competitively inhibits dihydrofolate reductase (DHFR) and thymidylate synthase. Subsequent depletion of thymidine monophosphate (TMP) occurs so that the cancer cell is unable to synthesize DNA and RNA. As a result, the cancer cell cannot proliferate and is forced to undergo apoptosis. Pralatrexate is more effective against cells that are actively dividing. Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer. or This study evaluated mechanistic differences between pralatrexate, methotrexate, and pemetrexed. Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methotrexate, and pemetrexed in NCI-H460 non-small cell lung cancer (NSCLC) cells. The tumor growth inhibition (TGI) was assessed using MV522 and NCI-H460 human NSCLC xenografts. Apparent K ( i ) values for DHFR inhibition were 45, 26, and >200 nM for pralatrexate, methotrexate, and pemetrexed, respectively. A significantly greater percentage of radiolabeled pralatrexate entered the cells and was polyglutamylatated relative to methotrexate or pemetrexed. In vivo, pralatrexate showed superior anti-tumor activity in both NSCLC models, with more effective dose-dependent TGI in the more rapidly growing NCI-H460 xenografts. Pralatrexate demonstrated a distinct mechanistic and anti-tumor activity profile relative to methotrexate and pemetrexed. Pralatrexate exhibited enhanced cellular uptake and increased polyglutamylation, which correlated with increased TGI in NSCLC xenograft models. Indications Treatment of relapsed or refractory peripheral T-cell lymphoma. Treatment of peripheral T-cell lymphoma, Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T-cell lymphomas. Pralatrexate is approved to treat: Peripheral T-cell lymphoma in patients whose disease is refractory (does not respond to treatment) or has recurred (come back). Pralatrexate is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on the overall response rate. Cutaneous T Cell Lymphomas (CTCL) Relapsed Peripheral T-Cell Lymphoma Refractory Peripheral T-cell Lymphoma Unspecified Use in Cancer Pralatrexate is approved to treat: Peripheral T-cell lymphoma in patients whose disease is refractory (does not respond to treatment) or has recurred (come back). This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pralatrexate provides a clinical benefit in these patients. Pralatrexate is also being studied in the treatment of other types of cancer. Contraindications Anemia, neutropenia, thrombocytopenia. Hematologic toxicity (e.g., thrombocytopenia, neutropenia, and anemia) has been reported with pralatrexate therapy Renal disease, renal impairment Hepatic disease Oral ulceration Tumor lysis syndrome (TLS) Serious rash. Geriatric. Pregnancy. anemia decreased blood platelets low levels of a type of white blood cell called neutrophils stomatitis, is a condition with painful swelling and sores inside the mouth abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding moderate to severe kidney impairment Dosage Strengths: 20 mg/mL Lymphoma Usual Adult Dose: 30 mg/m2 via intravenous push over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles. Duration: Until disease progression or unacceptable toxicity. Patients should take low doses (1 mg to 1.25 mg) of oral folic acid daily. Folic acid should start 10 days before the first dose of pralatrexate and continue for 30 days after the last dose. Patients should also receive a B12 (1 mg) injection within 10 weeks before the first dose of pralatrexate and every 8 to 10 weeks thereafter. Subsequent B12 injections may be given the same day as treatment with pralatrexate Dose Adjustments Management of severe or intolerable adverse reactions may require dose omission, reduction, or interruption of pralatrexate therapy. Doses may be omitted or reduced based on patient tolerance. Omitted doses will not be made up at the end of the cycle. Once a dose reduction occurs for toxicity, do not re-escalate. Dose Modifications for Mucositis: A) If mucositis is grade 2 on the day of treatment, omit the dose. Upon recovery to grade 1 or less, continue the prior dose. B) If mucositis is a recurrence of grade 2 on the day of treatment, omit the dose. Upon recovery to grade 1 or less, treatment may be resumed at 20 mg/m2. C) If mucositis is grade 3 on the day of treatment, omit the dose. Upon recovery to grade 1 or less, treatment may be resumed at 20 mg/m2. D) If mucositis is grade 4 on the day of treatment, therapy should be discontinued. Dose Modifications for Hematologic Toxicities: 1) Blood count on day of treatment reveals a platelet less than 50,000/mcL: A) If the duration of the toxicity is 1 week, omit the dose. Upon restart, continue the prior dose. B) If the duration of the toxicity is 2 weeks, omit the dose. Upon restart, treatment may be resumed at 20 mg/m2. C) If the duration of the toxicity is 3 weeks, therapy should be discontinued. 2) ANC is 500 to 1,000/mcL and no fever: If the duration of the toxicity is 1 week, omit the dose. Upon restart, continue the prior dose. 3) ANC 500 to 1,000/mcL with fever or ANC less than 500/mcL: A) If the duration of the toxicity is 1 week, omit the dose and give G-CSF or GM-CSF support. Upon restart, continue the prior dose with G-CSF or GM-CSF support. B) If the duration of the toxicity is 2 weeks or a recurrence, omit the dose and give G-CSF or GM-CSF support. Upon restart, treatment may be resumed at 20 mg/m2 with G-CSF or GM-CSF support. C) If the duration of the toxicity is 3 weeks or a second recurrence, therapy should be discontinued. 4) Dose modifications for all other treatment-related toxicities: A) If the toxicity is grade 3, omit the dose. Upon restart, treatment may be resumed at 20 mg/m2. B) If toxicity is grade 4, therapy should be discontinued. Administration advice: Prior to administering any dose of pralatrexate: 1) Mucositis should be grade 1 or less. 2) The platelet count should be greater than or equal to 100,000/mcL for the first dose and greater than or equal to 50,000/mcL for all subsequent doses. 3) The absolute neutrophil count (ANC) should be greater than or equal to 1,000/mcL. Side Effects The Most Common nausea vomiting diarrhea constipation decreased appetite tiredness weakness rash itching night sweats stomach, back, arm, or leg pain swelling of the hands, feet, ankles, or lower legs white patches or sores on the lips or in the mouth and throat fever, sore throat, cough, chills, or other signs of infection unusual bleeding or bruising bleeding gums nosebleeds small red or purple dots on the skin blood in the urine or stool shortness of breath chest pain fast or irregular heartbeat pale skin cold hands and feet extreme thirst dry, sticky mouth sunken eyes decreased urination dizziness or lightheadedness More common Black, tarry stools bleeding gums blood in the urine or stools body aches or pain chills convulsions cough cracked lips decreased urine diarrhea difficult or labored breathing difficulty with swallowing dry mouth ear congestion fast, pounding, or irregular heartbeat or pulse fever headache increased thirst loss of appetite loss of voice lower back or side pain mood changes muscle pain or cramps nasal congestion nausea or vomiting numbness or tingling in the hands, feet, or lips painful or difficult urination pale skin pinpoint red spots on the skin runny nose shortness of breath sneezing sore throat sores, ulcers, or white spots on the lips, tongue, or inside the mouth swelling tightness in the chest troubled breathing with exertion unusual bleeding or bruising unusual tiredness or weakness Abdominal or stomach pain back pain bloody nose constipation itching skin lack or loss of strength night sweats pain in the arms or legs rash weight loss Drug Interactions DRUG INTERACTION Abacavir Abacavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Pralatrexate. Abemaciclib Abemaciclib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Acetazolamide The therapeutic efficacy of Pralatrexate can be increased when used in combination with Acetazolamide. Acetylsalicylic acid The serum concentration of Pralatrexate can be increased when it is combined with Acetylsalicylic acid. Aclidinium Pralatrexate may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Pralatrexate may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Pralatrexate. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pralatrexate. Afatinib Afatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Albutrepenonacog Pralatrexate may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pralatrexate. Alectinib Alectinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Pralatrexate. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pralatrexate. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Pralatrexate. Allopurinol Allopurinol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Almasilate Pralatrexate may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Almotriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Alogliptin Alogliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Alprazolam Alprazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Pralatrexate. Amantadine Amantadine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Amikacin Pralatrexate may decrease the excretion rate of Amikacin which could result in a higher serum level. Amiloride Amiloride may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Aminophenazone Aminophenazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Aminosalicylic acid The serum concentration of Pralatrexate can be increased when it is combined with Aminosalicylic acid. Amitriptyline Amitriptyline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ammonium c Ammonium chloride may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Amoxicillin Amoxicillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ampicillin Ampicillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Amrinone Amrinone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Pralatrexate. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Pralatrexate. Ancestim Pralatrexate may decrease the excretion rate of Ancestim which could result in a higher serum level. Anifrolumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Anifrolumab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pralatrexate. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Pralatrexate. Antihemophilic Pralatrexate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. Antilymphocyte The risk or severity of adverse effects can be increased when Pralatrexate is combined with Antilymphocyte immunoglobulin (horse). Antipyrine Antipyrine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Antithrombin Pralatrexate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pralatrexate. Antrafenine Antrafenine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Apalutamide Apalutamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Pralatrexate. Arformoterol Arformoterol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pralatrexate. Articaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Articaine. COVID-19 Vacci The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Pralatrexate. Atazanavir Atazanavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Atomoxetine Atomoxetine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Auranofin Auranofin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Aurothioglucose Pralatrexate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Avanafil Avanafil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Avatrombopag Avatrombopag may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Pralatrexate. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Pralatrexate. Azelaic acid Azelaic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Aztreonam Aztreonam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Bacillus calmett The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Pralatrexate. Bacillus liv antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Pralatrexate. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pralatrexate. Bacitracin Bacitracin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Baclofen Baclofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Balsalazide The serum concentration of Pralatrexate can be increased when it is combined with Balsalazide. Baricitinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Pralatrexate. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Pralatrexate. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pralatrexate. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Pralatrexate. Belimumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Pralatrexate. Belumosudil The risk or severity of adverse effects can be increased when Pralatrexate is combined with Belumosudil. Bendamustine The risk or severity of adverse effects can be increased when Bendamustine is combined with Pralatrexate. Bendroflumethia Bendroflumethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Benserazide Pralatrexate may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine Benzatropine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Benznidazole Pralatrexate may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Benzocaine. Benzthiazide Benzthiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Benzyl alcohol. Bepotastine Bepotastine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Pralatrexate. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Pralatrexate. Bicisate Pralatrexate may decrease the excretion rate of Bicisate which could result in a higher serum level. Bimekizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Bimekizumab. Bismuth subgallate Pralatrexate may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bismuth subsalicylate The serum concentration of Pralatrexate can be increased when it is combined with Bismuth subsalicylate. Bisoprolol Bisoprolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Bisoxatin Pralatrexate may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Pralatrexate. Blinatumomab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Pralatrexate. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Pralatrexate. Bosutinib The risk or severity of adverse effects can be increased when Bosutinib is combined with Pralatrexate. Brentuximab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brentuximab vedotin. Brigatinib Brigatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Brivaracetam Brivaracetam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brodalumab. Bromazepam Bromazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Bromotheophylline Bromotheophylline may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Pralatrexate. Bumadizone Bumadizone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Bumetanide Bumetanide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Bupivacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Bupropion Bupropion may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Buspirone Buspirone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Pralatrexate. Butabarbital Butabarbital may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pralatrexate. Caffeine Caffeine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Canagliflozin Canagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Pralatrexate. Cannabidiol Cannabidiol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Canrenoic acid Canrenoic acid may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Pralatrexate. Capmatinib The serum concentration of Pralatrexate can be increased when it is combined with Capmatinib. Capreomycin Pralatrexate may decrease the excretion rate of Capreomycin which could result in a higher serum level. Capsaicin The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pralatrexate. Carbidopa Carbidopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Pralatrexate. Carfilzomib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Pralatrexate. Carprofen Carprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefaclor Cefaclor may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefadroxil Cefadroxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefalotin Cefalotin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefamandole Cefamandole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefapirin Cefapirin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefazolin Cefazolin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefdinir Cefdinir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefoperazone Cefoperazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceforanide Ceforanide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefotaxime Cefotaxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefotetan Cefotetan may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefotiam Cefotiam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefoxitin Cefoxitin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceftaroline Ceftaroline fosamil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceftibuten Ceftibuten may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceftizoxime Ceftizoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceftobiprole Ceftobiprole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ceftolozane Pralatrexate may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone Ceftriaxone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cefuroxime Cefuroxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cephalexin Cephalexin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cephaloglycin Cephaloglycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Certolizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Certolizumab pegol. Cetirizine Cetirizine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cevimeline Cevimeline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Chloral hydrate Chloral hydrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pralatrexate. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Pralatrexate. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Chloroprocaine. Chloroquine Chloroquine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Pralatrexate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpromazine Chlorpromazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Chlorpropamide Chlorpropamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Chlorthalidone Chlorthalidone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cholesterol Cholesterol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Choline C 11 Pralatrexate may decrease the excretion rate of Choline C 11 which could result in a higher serum level. Choline magnesium Choline magnesium trisalicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Choline salicylate The serum concentration of Pralatrexate can be increased when it is combined with Choline salicylate. Chondroitin sulfate Pralatrexate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Pralatrexate may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Pralatrexate may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Pralatrexate may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium gluconate Pralatrexate may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicotinate Pralatrexate may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Chromous sulfate Pralatrexate may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pralatrexate. You Might Also Read How To Obtain Rid Of Belly Fats - Steps To Remove That Excess Belly Fat Cidofovir Cidofovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cilostazol Cilostazol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cimetidine Cimetidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cinchocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Cinchocaine. Ciprofloxacin Ciprofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Pralatrexate. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Pralatrexate. Clevidipine Clevidipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Clobazam Clobazam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Clobetasol The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pralatrexate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Pralatrexate. Clofazimine Clofazimine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Clomipramine Clomipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Clonazepam Clonazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Clorazepic acid Clorazepic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate. Clove oil Pralatrexate may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine Clozapine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cobicistat Cobicistat may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Cocaine. Colchicine Colchicine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Colistin Pralatrexate may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. C estrogens Conjugated estrogens may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Corifollitropin alfa Pralatrexate may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Corticotropin The risk or severity of adverse effects can be increased when Corticotropin is combined with Pralatrexate. Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pralatrexate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate. Cyanocobalamin Cyanocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pralatrexate. Cyclosporine Pralatrexate may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide Cyclothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Pralatrexate. Dabigatran Dabigatran etexilate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dabrafenib Dabrafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Pralatrexate. Daclatasvir Daclatasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dacomitinib Dacomitinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pralatrexate. Dalfampridine Dalfampridine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dapagliflozin Dapagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralatrexate. Darolutamide Darolutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dasabuvir Dasabuvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Pralatrexate. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Pralatrexate. Deferiprone Pralatrexate may decrease the excretion rate of Deferiprone which could result in a higher serum level. Deflazacort The risk or severity of adverse effects can be increased when Pralatrexate is combined with Deflazacort. Delafloxacin Pralatrexate may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Pralatrexate. Desipramine Desipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Desmopressin Desmopressin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Pralatrexate. Desvenlafaxine Desvenlafaxine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Deucravacitinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Deucravacitinib. Deutetrabenazine Pralatrexate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pralatrexate. Dexamethasone Dexamethasone acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dexibuprofen Dexibuprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dexmedetomidine Dexmedetomidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dexpanthenol Pralatrexate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pralatrexate. Dextran Pralatrexate may decrease the excretion rate of Dextran which could result in a higher serum level. Diatrizoate Diatrizoate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Diazepam Diazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dichlorobenzyl Pralatrexate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac Diclofenac may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Diclofenamide Diclofenamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Dicyclomine Dicyclomine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Didanosine Didanosine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dienogest Pralatrexate may decrease the excretion rate of Dienogest which could result in a higher serum level. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Diflunisal The serum concentration of Pralatrexate can be increased when it is combined with Diflunisal. Difluocortolone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Difluocortolone. Digoxin Pralatrexate may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dimercaprol Dimercaprol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dimethyl fumarate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Dimethyl fumarate. Dimethyl sulfoxide Dimethyl sulfoxide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dinutuximab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Diphenhydramine. Diroximel fumarate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Diroximel fumarate. Disopyramide Disopyramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. DL-Methylephedrine Pralatrexate may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Dobutamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate. Dopamine Dopamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Doripenem Doripenem may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Doxacurium Doxacurium may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Doxepin Doxepin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Pralatrexate. Doxycycline Doxycycline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Drospirenone Drospirenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Droxidopa Droxidopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Duloxetine Duloxetine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Dyclonine. Dyphylline Dyphylline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pralatrexate. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Pralatrexate. Edoxaban Pralatrexate may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Edrophonium may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Pralatrexate. Elbasvir Elbasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Eltrombopag Eltrombopag may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Emapalumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Emapalumab. Enalaprilat Pralatrexate may decrease the excretion rate of Enalaprilat which could result in a higher serum level. Enasidenib Enasidenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Enzalutamide Pralatrexate may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Pralatrexate. Eplerenone Eplerenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol Epoprostenol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Eribulin The risk or severity of adverse effects can be increased when Pralatrexate is combined with Eribulin. Erlotinib Erlotinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ertapenem Ertapenem may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pralatrexate. Estazolam Estazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estradiol Estradiol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estradiol benzoate Estradiol benzoate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estradiol cypionate Estradiol cypionate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estradiol dienanthate Estradiol dienanthate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estradiol valerate Estradiol valerate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Pralatrexate. Estrone sulfate Estrone sulfate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Eszopiclone Eszopiclone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Etacrynic acid Etacrynic acid may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Etafedrine Pralatrexate may decrease the excretion rate of Etafedrine which could result in a higher serum level. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Pralatrexate. Ethambutol Ethambutol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Etidocaine. Etodolac Etodolac may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Etomidate Etomidate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Etonogestrel Etonogestrel may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Pralatrexate. Etoricoxib Etoricoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Eucalyptus oil Pralatrexate may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Pralatrexate. Ezogabine Ezogabine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Pralatrexate. Febuxostat The excretion of Pralatrexate can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fenbufen Fenbufen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fenofibrate Fenofibrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fenofibric acid Pralatrexate may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam Fenoldopam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fenoprofen Fenoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fentanyl Fentanyl may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fesoterodine Fesoterodine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Filgotinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Filgotinib. Finerenone Finerenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Fingolimod Pralatrexate may increase the immunosuppressive activities of Fingolimod. Flavoxate Flavoxate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Floctafenine Floctafenine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Florbetaben Pralatrexate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir Pralatrexate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Pralatrexate. Fluconazole Fluconazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Pralatrexate. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Pralatrexate. Fludeoxyglucose Pralatrexate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pralatrexate. Flumazenil Flumazenil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Pralatrexate. Fluocinolone The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Pralatrexate. Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pralatrexate. Fluocortolone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Pralatrexate. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pralatrexate. Fluprednisolone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluprednisolone. Flurazepam Flurazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Flurbiprofen Flurbiprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Flutamide Flutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fluticasone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluticasone. Fluticasone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluticasone furoate. Fluticasone The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pralatrexate. Fluvoxamine Fluvoxamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Folic acid The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Folic acid. Fomepizole Fomepizole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fondaparinux Fondaparinux may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Formestane Pralatrexate may decrease the excretion rate of Formestane which could result in a higher serum level. Foscarnet Foscarnet may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fosfomycin Fosfomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fosinopril Fosinopril may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fostamatinib Fostamatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Fostemsavir Fostemsavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Framycetin Framycetin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Furosemide Furosemide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Fusidic acid Fusidic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gabapentin Pralatrexate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid Gadobenic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gadodiamide Gadodiamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gadofosveset Gadofosveset trisodium may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gadopentetic acid Gadopentetic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gadoteric acid Pralatrexate may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. Gadoteridol Gadoteridol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Pralatrexate. Ganciclovir Ganciclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gefitinib Gefitinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pralatrexate. Gemfibrozil Gemfibrozil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate. Gentamicin Pralatrexate may decrease the excretion rate of Gentamicin which could result in a higher serum level. Gilteritinib Gilteritinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Gimeracil Pralatrexate may decrease the excretion rate of Gimeracil which could result in a higher serum level. Givosiran Givosiran may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Glasdegib Glasdegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Pralatrexate. Glecaprevir Glecaprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Glipizide Glipizide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Glucarpidase The serum concentration of the active metabolites of Pralatrexate can be reduced when Pralatrexate is used in combination with Glucarpidase resulting in a loss in efficacy. Glycerol Pralatrexate may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. Glycol salicylate Glycol salicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Pralatrexate. Golodirsen Pralatrexate may decrease the excretion rate of Golodirsen which could result in a higher serum level. Goserelin Goserelin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Grazoprevir Grazoprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Guanethidine Guanethidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Guanfacine Guanfacine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Guselkumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pralatrexate. Haloperidol Haloperidol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pralatrexate. Hepatitis B The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pralatrexate. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pralatrexate. Hydralazine Hydralazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Hydrochlorothiazide Hydrochlorothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Hydrocortisone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone butyrate. Hydrocortisone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone succinate. Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Hydromorphone Hydromorphone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Hydroxocobalamin Hydroxocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pralatrexate. Hydroxyethyl Starch Pralatrexate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Pralatrexate. Ibritumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate. Ibrutinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ibrutinib. Ibuprofen Ibuprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ibutilide Ibutilide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Icatibant Icatibant may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Icosapent Icosapent may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Pralatrexate. Idarucizumab Pralatrexate may decrease the excretion rate of Idarucizumab which could result in a higher serum level. Idebenone Pralatrexate may decrease the excretion rate of Idebenone which could result in a higher serum level. Idelalisib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Pralatrexate. Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Pralatrexate. Imipramine Imipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Indapamide Indapamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Indigotindisulfonic Pralatrexate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. Indomethacin Indomethacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Inebilizumab The risk or severity of infection can be increased when Pralatrexate is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Pralatrexate. You Might Also Read Ursodeoxycholic Acid; Uses, Dosage, Side Effects, Interactions Isradipine Isradipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Istradefylline Istradefylline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Itraconazole Itraconazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ixabepilone The risk or severity of adverse effects can be increased when Ixabepilone is combined with Pralatrexate. Ixazomib Pralatrexate may decrease the excretion rate of Ixazomib which could result in a higher serum level. Ixekizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ixekizumab. COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Pralatrexate. J encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate. Kanamycin Pralatrexate may decrease the excretion rate of Kanamycin which could result in a higher serum level. Ketamine Ketamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ketazolam Ketazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ketoprofen Ketoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ketorolac Ketorolac may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Labetalol Labetalol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lamivudine Lamivudine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lamotrigine Lamotrigine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lansoprazole Lansoprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lasmiditan The serum concentration of Pralatrexate can be increased when it is combined with Lasmiditan. Latamoxef Latamoxef may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ledipasvir Ledipasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Leflunomide The risk or severity of adverse effects can be increased when Pralatrexate is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pralatrexate. Lesinurad Pralatrexate may decrease the excretion rate of Lesinurad which could result in a higher serum level. Letermovir Letermovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Leucovorin The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Leucovorin. Leuprolide Leuprolide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Levobupivacaine. Levocarnitine Levocarnitine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Levocetirizine Levocetirizine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Levofloxacin Levofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Levoleucovorin The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Levoleucovorin. Levomilnacipran Pralatrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. Levosalbutamol Pralatrexate may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. Lidocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Lidocaine. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Pralatrexate. Liothyronine Liothyronine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lisinopril Lisinopril may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lithium carbonate Pralatrexate may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate Lithium citrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lixisenatide Pralatrexate may decrease the excretion rate of Lixisenatide which could result in a higher serum level. Lofexidine Lofexidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Pralatrexate. Lopinavir The serum concentration of Pralatrexate can be increased when it is combined with Lopinavir. Loracarbef Loracarbef may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lorazepam Lorazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lorcaserin Lorcaserin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lornoxicam Lornoxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lorpiprazole Pralatrexate may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. Loxoprofen Loxoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lubiprostone Lubiprostone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Lumiracoxib Lumiracoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Macitentan Pralatrexate may decrease the excretion rate of Macitentan which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Pralatrexate. Magnesium Pralatrexate may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chlo Pralatrexate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium Pralatrexate may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium tris Pralatrexate may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Mangafodipir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Mannitol Mannitol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Maprotiline Maprotiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Maribavir Maribavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Pralatrexate. Mecamylamine Mecamylamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pralatrexate. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Medroxyprogeste Medroxyprogesterone acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Mefenamic acid Mefenamic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Megestrol acetate Megestrol acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Meloxicam Meloxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Pralatrexate. Memantine Memantine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Pralatrexate. Menthyl salicylate Menthyl salicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Meperidine Meperidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Mepivacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Pralatrexate. Meprednisone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Pralatrexate. Meropenem Meropenem may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Mesalazine The serum concentration of Pralatrexate can be increased when it is combined with Mesalazine. Metamfetamine Metamfetamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Metaxalone Metaxalone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Metformin Metformin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Methadone Methadone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Methazolamide Methazolamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Pralatrexate. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Pralatrexate. Methoxsalen Methoxsalen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralatrexate. Methyl salicylate The serum concentration of Pralatrexate can be increased when it is combined with Methyl salicylate. Methyldopa Methyldopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Methylene blue Pralatrexate may decrease the excretion rate of Methylene blue which could result in a higher serum level. Methylnaltrexone Methylnaltrexone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pralatrexate. Methyltestosterone Methyltestosterone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Meticrane Meticrane may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Metoclopramide Metoclopramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Metolazone Metolazone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Metoprolol Metoprolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Metyrapone Metyrapone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Midazolam Midazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Migalastat Migalastat may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Milnacipran Milnacipran may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Milrinone Milrinone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Mirabegron Pralatrexate may decrease the excretion rate of Mirabegron which could result in a higher serum level. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Pralatrexate. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pralatrexate. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Pralatrexate. accinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pralatrexate. Mometasone The risk or severity of adverse effects can be increased when Pralatrexate is combined with Mometasone furoate. Monomethyl The risk or severity of adverse effects can be increased when Pralatrexate is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Mosunetuzumab. Moxisylyte Pralatrexate may decrease the excretion rate of Moxisylyte which could result in a higher serum level. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Pralatrexate. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Pralatrexate. Muzolimine Muzolimine may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Mycophenolate The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pralatrexate. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pralatrexate. N-acetyltyrosine Pralatrexate may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. Nabumetone Nabumetone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nadolol Nadolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Naldemedine Pralatrexate may decrease the excretion rate of Naldemedine which could result in a higher serum level. Nalmefene Nalmefene may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Naloxone Naloxone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Naproxen Naproxen may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Natalizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab. Nateglinide Nateglinide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nedaplatin Pralatrexate may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Nedocromil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nefazodone Nefazodone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Pralatrexate. Nelfinavir Nelfinavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Neomycin Pralatrexate may decrease the excretion rate of Neomycin which could result in a higher serum level. Netilmicin Pralatrexate may decrease the excretion rate of Netilmicin which could result in a higher serum level. Nicorandil Pralatrexate may decrease the excretion rate of Nicorandil which could result in a higher serum level. Nifedipine Nifedipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nilotinib The risk or severity of adverse effects can be increased when Nilotinib is combined with Pralatrexate. Nilutamide Nilutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nimesulide Nimesulide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nisoldipine Nisoldipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nitric Oxide Nitric Oxide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nitroprusside Nitroprusside may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Novobiocin Novobiocin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Pralatrexate. Obinutuzumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Pralatrexate. Octinoxate Pralatrexate may decrease the excretion rate of Octinoxate which could result in a higher serum level. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pralatrexate. Olaparib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Olaparib. Olsalazine The serum concentration of Pralatrexate can be increased when it is combined with Olsalazine. Omeprazole Omeprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Opium Pralatrexate may decrease the excretion rate of Opium which could result in a higher serum level. Oseltamivir Oseltamivir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Osimertinib Osimertinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Oteseconazole The serum concentration of Pralatrexate can be increased when it is combined with Oteseconazole. Oxacillin Oxacillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pralatrexate. Oxaprozin Oxaprozin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Oxazepam Oxazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Oxetacaine. Oxybenzone Oxybenzone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Oxybuprocaine. Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Oxyquinoline Pralatrexate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Ozanimod The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pralatrexate. Pacritinib The serum concentration of Pralatrexate can be increased when it is combined with Pacritinib. Palbociclib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Palbociclib. Paliperidone Paliperidone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Palonosetron Palonosetron may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pamidronic acid Pamidronic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Pralatrexate. Pantoprazole Pantoprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Parecoxib Parecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Paritaprevir Paritaprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Paromomycin Paromomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Patent Blue Pralatrexate may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pazopanib The risk or severity of adverse effects can be increased when Pazopanib is combined with Pralatrexate. Pegaptanib Pegaptanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pralatrexate. Pegcetacoplan The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pralatrexate. Peginterferon alfa The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pralatrexate. Peginterferon alfa The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pralatrexate. Peginterferon beta The risk or severity of adverse effects can be increased when Pralatrexate is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Pralatrexate. Penbutolol Penbutolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Pralatrexate. Pentaerythritol Pentaerythritol tetranitrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pentamidine Pentamidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pentastar Pralatrexate may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Pralatrexate may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Pentobarbital may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Pralatrexate. Pentoxifylline Pentoxifylline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Perindopril Perindopril may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Permethrin Permethrin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Pralatrexate. Phenelzine Phenelzine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Phenol The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Phenol. Phentolamine Phentolamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Phenyl aminosalicy The serum concentration of Pralatrexate can be increased when it is combined with Phenyl aminosalicylate. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pralatrexate. Phenylbutazone Phenylbutazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pholcodine Pralatrexate may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Pralatrexate may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Phylloquinone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pibrentasvir Pibrentasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Picosulfuric acid Pralatrexate may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pralatrexate. Pindolol Pindolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Piperacillin Piperacillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Piracetam Pralatrexate may decrease the excretion rate of Piracetam which could result in a higher serum level. Piretanide Piretanide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pralatrexate. Piroxicam Piroxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pitolisant Pralatrexate may decrease the excretion rate of Pitolisant which could result in a higher serum level. Plazomicin Pralatrexate may decrease the excretion rate of Plazomicin which could result in a higher serum level. Plerixafor Plerixafor may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Polythiazide Polythiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Pomalidomide The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ponesimod. Potassium Potassium may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Potassium acetate Pralatrexate may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Potassium Pralatrexate may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. Potassium cation Potassium cation may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Potassium chloride Potassium chloride may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Potassium citrate Potassium citrate may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Potassium nitrate Pralatrexate may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. Potassium Pralatrexate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Potassium sulfate Pralatrexate may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Pralidoxime Pralidoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib Pralsetinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pramipexole Pramipexole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Pramocaine. Prasugrel Prasugrel may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pravastatin Pravastatin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Pralatrexate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Pralatrexate. Pregabalin Pregabalin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Prilocaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Prilocaine. Probenecid The serum concentration of Pralatrexate can be increased when it is combined with Probenecid. Procainamide Pralatrexate may decrease the excretion rate of Procainamide which could result in a higher serum level. Procaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Procaine. Procaine Pralatrexate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Pralatrexate. Progesterone Progesterone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Promethazine Promethazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Propantheline Propantheline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Proparacaine. Propiverine Pralatrexate may decrease the excretion rate of Propiverine which could result in a higher serum level. Propoxycaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Propoxycaine. Propranolol Propranolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pralatrexate. Prucalopride Prucalopride may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pyrantel Pralatrexate may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Pyrazinamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pyridoxine Pyridoxine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pyrithione Pralatrexate may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine Quetiapine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Quinethazone Quinethazone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Quinidine Pralatrexate may decrease the excretion rate of Quinidine which could result in a higher serum level. Rabeprazole Rabeprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Rabies i The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Pralatrexate. Rabies antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pralatrexate. Rabies antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pralatrexate. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pralatrexate. Ramelteon Ramelteon may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ranitidine Ranitidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ranolazine Ranolazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Rasagiline Rasagiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ravulizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ravulizumab. Regorafenib Regorafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Reserpine Reserpine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Resorcinol Pralatrexate may decrease the excretion rate of Resorcinol which could result in a higher serum level. Ribavirin Ribavirin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ribostamycin Pralatrexate may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Rilonacept The risk or severity of adverse effects can be increased when Rilonacept is combined with Pralatrexate. Rilpivirine Rilpivirine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ripretinib Ripretinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Risankizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Risankizumab. Ritonavir Ritonavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Pralatrexate. Rivaroxaban Rivaroxaban may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Rizatriptan Rizatriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Rofecoxib Rofecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Roflumilast Roflumilast may increase the immunosuppressive activities of Pralatrexate. Rolapitant Rolapitant may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ropeginterferon The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Ropivacaine. Rosiglitazone Rosiglitazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pralatrexate. Roxadustat The serum concentration of Pralatrexate can be increased when it is combined with Roxadustat. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pralatrexate. Rucaparib Rucaparib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Ruxolitinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ruxolitinib. You Might Also Read Vitamin B1 Health Benefits, Which Fruits Contains Vitamin B1 Sacubitril Pralatrexate may decrease the excretion rate of Sacubitril which could result in a higher serum level. Safinamide Safinamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Salbutamol Salbutamol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Salicylamide Salicylamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Salicylic acid The serum concentration of Pralatrexate can be increased when it is combined with Salicylic acid. Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sapropterin The serum concentration of Sapropterin can be decreased when it is combined with Pralatrexate. Saquinavir Saquinavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Satralizumab. Saxagliptin Saxagliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Secobarbital Secobarbital may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Secukinumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Secukinumab. Selenious acid Pralatrexate may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Pralatrexate may decrease the excretion rate of Selenium which could result in a higher serum level. Sibutramine Sibutramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Siltuximab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Siltuximab. Simeprevir Simeprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Siponimod The risk or severity of adverse effects can be increased when Pralatrexate is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pralatrexate. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Pralatrexate. Sitagliptin Sitagliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Pralatrexate. Sodium acetate Pralatrexate may decrease the excretion rate of Sodium acetate which could result in a higher serum level. Sodium Pralatrexate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. Sodium fluoride Pralatrexate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. Sodium sulfate Pralatrexate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Sofosbuvir Pralatrexate may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol Pralatrexate may decrease the excretion rate of Solriamfetol which could result in a higher serum level. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Pralatrexate. Sorbitol Sorbitol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sotagliflozin Sotagliflozin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sotorasib The serum concentration of Pralatrexate can be increased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Spesolimab. Spironolactone Spironolactone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol The excretion of Pralatrexate can be decreased when combined with Stiripentol. Streptomycin Pralatrexate may decrease the excretion rate of Streptomycin which could result in a higher serum level. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Pralatrexate. Strontium chloride Pralatrexate may decrease the excretion rate of Strontium chloride which could result in a higher serum level. Sucralfate Sucralfate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sulbactam Pralatrexate may decrease the excretion rate of Sulbactam which could result in a higher serum level. Sulfadiazine Sulfadiazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sulfamethoxazole Pralatrexate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level. Sulfasalazine The serum concentration of Pralatrexate can be increased when it is combined with Sulfasalazine. Sulindac Sulindac may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sumatriptan Sumatriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Sunitinib The risk or severity of adverse effects can be increased when Sunitinib is combined with Pralatrexate. SEstrogens, A Pralatrexate may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. SEstrogens, B Pralatrexate may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Pralatrexate. Tadalafil Tadalafil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tafamidis The serum concentration of Pralatrexate can be increased when it is combined with Tafamidis. Tamsulosin Tamsulosin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tasimelteon Pralatrexate may decrease the excretion rate of Tasimelteon which could result in a higher serum level. Taurocholic acid Taurocholic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Technetium Pralatrexate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. Technetium Pralatrexate may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. Technetium Pralatrexate may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. Technetium Pralatrexate may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Teduglutide Pralatrexate may decrease the excretion rate of Teduglutide which could result in a higher serum level. Tegafur Pralatrexate may decrease the excretion rate of Tegafur which could result in a higher serum level. Telavancin Telavancin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Telmisartan Telmisartan may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Temazepam Temazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Pralatrexate. Temsirolimus The risk or severity of adverse effects can be increased when Temsirolimus is combined with Pralatrexate. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Pralatrexate. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralatrexate. Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tenoxicam Tenoxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tepotinib Tepotinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pralatrexate. Terbutaline Terbutaline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Teriflunomide The risk or severity of adverse effects can be increased when Pralatrexate is combined with Teriflunomide. Testolactone Testolactone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Testosterone Testosterone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Testosterone Pralatrexate may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Pralatrexate may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Testosterone Testosterone propionate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Testosterone Pralatrexate may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. Tetracaine The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Tetracaine. Tetracycline Tetracycline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tetradecyl Pralatrexate may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Pralatrexate. Thiabendazole Thiabendazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Thiethylperazine Thiethylperazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Pralatrexate. Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tick- encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Pralatrexate. Ticlopidine Ticlopidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tiludronic acid Tiludronic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Timolol Timolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tinidazole Tinidazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Pralatrexate. Tiopronin Pralatrexate may decrease the excretion rate of Tiopronin which could result in a higher serum level. Tiotropium Tiotropium may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tirofiban Tirofiban may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tivozanib Tivozanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Pralatrexate is combined with Tixocortol. Tobramycin Pralatrexate may decrease the excretion rate of Tobramycin which could result in a higher serum level. Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Pralatrexate. Tocopherol Pralatrexate may decrease the excretion rate of Tocopherol which could result in a higher serum level. Tofacitinib Pralatrexate may increase the immunosuppressive activities of Tofacitinib. Tolazamide Tolazamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tolbutamide Tolbutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tolcapone Tolcapone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tolmetin Tolmetin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tolterodine Tolterodine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tolvaptan Tolvaptan may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Topiramate Topiramate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Pralatrexate. Torasemide Torasemide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Pralatrexate. Trabectedin The risk or severity of adverse effects can be increased when Trabectedin is combined with Pralatrexate. Tramadol Tramadol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Trametinib Pralatrexate may decrease the excretion rate of Trametinib which could result in a higher serum level. Trastuzumab Trastuzumab may increase the neutropenic activities of Pralatrexate. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pralatrexate. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Pralatrexate. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Pralatrexate. Triamterene Triamterene may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Triazolam Triazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Trichlormethiazide Trichlormethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Triethylenetetram Pralatrexate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Pralatrexate. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Pralatrexate. Trimebutine Pralatrexate may decrease the excretion rate of Trimebutine which could result in a higher serum level. Trimethoprim Trimethoprim may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Trimetrexate Trimetrexate may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Tropisetron Pralatrexate may decrease the excretion rate of Tropisetron which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pralatrexate. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pralatrexate. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pralatrexate. Upadacitinib The risk or severity of adverse effects can be increased when Pralatrexate is combined with Upadacitinib. Vaborbactam Pralatrexate may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Valaciclovir Valaciclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Valbenazine Pralatrexate may decrease the excretion rate of Valbenazine which could result in a higher serum level. Valdecoxib Valdecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Valganciclovir Valganciclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Vancomycin Pralatrexate may decrease the excretion rate of Vancomycin which could result in a higher serum level. Vandetanib Vandetanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Varenicline Varenicline may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Pralatrexate. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Pralatrexate. Vedolizumab The risk or severity of adverse effects can be increased when Pralatrexate is combined with Vedolizumab. Velpatasvir Velpatasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Vemurafenib Vemurafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Venetoclax Venetoclax may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Venlafaxine Venlafaxine may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Verapamil Verapamil may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Vibrio antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pralatrexate. Vilanterol The risk or severity of adverse effects can be increased when Pralatrexate is combined with Vilanterol. Viloxazine Pralatrexate may decrease the excretion rate of Viloxazine which could result in a higher serum level. Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Pralatrexate. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Pralatrexate. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Pralatrexate. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pralatrexate. Vismodegib Vismodegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Voclosporin The risk or severity of adverse effects can be increased when Pralatrexate is combined with Voclosporin. Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Pralatrexate. Vortioxetine Pralatrexate may decrease the excretion rate of Vortioxetine which could result in a higher serum level. Voxilaprevir Voxilaprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Warfarin Pralatrexate may decrease the excretion rate of Warfarin which could result in a higher serum level. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pralatrexate. Zaleplon Zaleplon may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Zanamivir Zanamivir may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Pralatrexate. Zonisamide Zonisamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. Pregnancy and Lactation FDA Pregnancy Category D Pregnancy FOLOTYN can cause fetal harm when administered to a pregnant woman. Pralatrexate was embryotoxic and fetotoxic in rats at IV doses of 0.06 mg/kg/day (0.36 mg/m2/day or about 1.2% of the clinical dose on an mg/m2 basis) given on gestation days 7 through 20. Treatment with pralatrexate caused a dose-dependent decrease in fetal viability manifested as an increase in late, early, and total resorptions. There was also a dose-dependent increase in post-implantation loss. In rabbits, IV doses of 0.03 mg/kg/day (0.36 mg/m2 /day) or greater given on gestation days 8 through 21 also caused abortion and fetal lethality. This toxicity manifested as early and total resorptions, post-implantation loss, and a decrease in the total number of live fetuses. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Lactation It is not known whether pralatrexate is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from this drug, a decision should be made whether to discontinue nursing or to discontinue FOLOTYN, taking into account the importance of FOLOTYN to the mother. How should this medicine be used? Pralatrexate injection comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given over a period of 3 to 5 minutes once a week for 6 weeks as part of a 7-week cycle. Your treatment will probably continue until your condition worsens or you develop serious side effects. Your doctor may need to adjust your dose, skip a dose, or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with a pralatrexate injection. You will need to take folic acid and vitamin B12 during your treatment with pralatrexate injection to help prevent certain side effects. Your doctor will probably tell you to take folic acid by mouth every day beginning 10 days before you start your treatment and for 30 days after your final dose of pralatrexate injection. Your doctor will also probably tell you that you will need to receive a vitamin B12 injection no more than 10 weeks before your first dose of pralatrexate injection and every 8 to 10 weeks for as long as your treatment continues. What special precautions should I follow? Before receiving a pralatrexate injection, tell your doctor and pharmacist if you are allergic to pralatrexate injection, any other medications, or any of the ingredients in pralatrexate injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: aspirin and other nonsteroidal anti-inflammatory medications (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); probenecid (Probalan), and trimethoprim/sulfamethoxazole (Bactrim). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had kidney or liver disease. tell your doctor if you are pregnant, could be pregnant, or plan to become pregnant. You should not become pregnant while you are receiving pralatrexate injections. Talk to your doctor about birth control methods that you can use during your treatment. If you become pregnant while receiving a pralatrexate injection, call your doctor immediately. Pralatrexate injection may harm the fetus. if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a pralatrexate injection. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022468lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022468s012lbl.pdf https://www.drugs.com/history/folotyn.html https://www.cancer.gov/about-cancer/treatment/drugs/pralatrexate https://pubchem.ncbi.nlm.nih.gov/compound/Pralatrexate https://pubchem.ncbi.nlm.nih.gov/compound/Pralatrexate https://go.drugbank.com/drugs/DB06813 https://www.drugs.com/mtm/pralatrexate.html https://medlineplus.gov/druginfo/meds/a610001.html https://en.wikipedia.org/wiki/Pralatrexate https://www.mayoclinic.org/drugs-supplements/pralatrexate-intravenous-route/side-effects/drg-20073415?p=1 https://www.webmd.com/drugs/2/drug-153046/pralatrexate-intravenous/details/list-contraindications CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ Pralatrexate https://commonchemistry.cas.org/detail?cas_rn=146464-95-1 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Pralatrexate [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/0146464951 https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Pralatrexate https://www.drugbank.ca/drugs/DB06813 DTP/NCI https://www.cancer.gov/policies/copyright-reuse Pralatrexate https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=754230 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Pralatrexate https://comptox.epa.gov/dashboard/DTXSID3048578 https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/210739 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking PRALATREXATE https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A8Q8I19Q20 Hazardous Substances Data Bank (HSDB) Pralatrexate https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7786 ChEBI Pralatrexate http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71223 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking PRALATREXATE https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Pralatrexate https://www.ncbi.nlm.nih.gov/books/n/livertox/Pralatrexate/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2250 NCI Thesaurus Tree https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201746/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp 10-propargyl-10-deazaaminopterin https://ctdbase.org/detail.go?type=chem&acc=C418863 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads PRALATREXATE https://www.dgidb.org/drugs/PRALATREXATE IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license pralatrexate https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6840 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Pralatrexate http://idrblab.net/ttd/data/drug/details/D02LWU ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html PRALATREXATE https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PRALATREXATE Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking pralatrexate https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Folotyn (EMEA/H/C/002096) https://www.ema.europa.eu/en/medicines/human/EPAR/folotyn EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking PRALATREXATE https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory MassBank of North America (MoNA) https://mona.fiehnlab.ucdavis.edu/documentation/license Pralatrexate(Folotyn) https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22OGSBUKJUDHAQEA-WMCAAGNKSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Folotyn (Pralatrexate) https://www.cancer.gov/about-cancer/treatment/drugs/pralatrexate NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html pralatrexate https://rxnav.nlm.nih.gov/id/rxnorm/662019 PubChem https://pubchem.ncbi.nlm.nih.gov Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=35052338-593811014 Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Pralatrexate https://www.wikidata.org/wiki/Q637059 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html 10-propargyl-10-deazaaminopterin https://www.ncbi.nlm.nih.gov/mesh/67418863 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 390746020 https://pubchem.ncbi.nlm.nih.gov/substance/390746020 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout h Show More